Panadol-extra

PreclinicalSmall molecule

DDamascus University

Panadol-extra is one of 3 small molecule programs targeting Pain and Discomfort. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pain and DiscomfortCompleted

Pain and DiscomfortPreclinical

Completed

Competition

Competitive Landscape

2 competitors in Pain and Discomfort

#DrugCompanyPhaseTrials

Nubain

AAultman Health Foundation

Preclinical

1 2

Nalbuphine and Flurbiprofen Axetil

SSun Yat-sen University

Preclinical

1 3

Panadol-extra

DDamascus University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pain and Discomfort1 trial

The Role of Paracetamol-caffeine and Laser Irradiation on Controlling Pain and Discomfort During Orthodontic Treatment

Completed·—·N/A·NCT03400111·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Panadol-extra. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Panadol-extra compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Panadol-extra. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Damascus University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: DDamascus University

Panadol-extra

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pain and Discomfort1 trial

References

Drug Info

Quick Facts

Related News